Italian pharmaceutical company buys rights to immunotherapy from Sanofi

Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).

By Samuel Lagercrantz

October 7, 2024 10:24 AM

Enjaymo (sutimlimab) is a biologic drug that is the only approved treatment for cold agglutinin disease. On Friday, Recordati announced that the company is acquiring the global rights for the drug from France's Sanofi for 825 million US dollars.

– This transaction is in-line with our broader strategy, reaffirms our commitment to the Rare Diseases space and is complementary to our oncology portfolio, says Rob Koremans, Chief Executive Officer of Recordati, in a press release.

Recordati, headquartered in Milan, Italy, is present in 150 countries. At the end of 2023, the company had 4,450 employees and had consolidated revenue of € 2,082.3 million.

{{ comments.count === 1 ? '1 comment' : comments.count > 1 ? '{0} comments'.replace('{0}', comments.count) : 'Write a comment' }}

By submitting the comment you accept the terms. See terms

Good comment behavior

Keep a good tone in your comments, avoid personal attacks and posts of marketing character. Apply only link on your comment if it is relevant to the debate.

Be aware that the debates are moderated by the portal's editorial team.

The comment has been created.

Your comment will not be visible until you activate it. In a few moments you will receive an email where you must click on a link to activate your comment.